论文部分内容阅读
目前，肺癌的发病率和病死率逐年升高。随着手术等综合治疗手段的进步，非小细胞肺癌（ NSCLC）的近期疗效得到了较大的改善，但远期疗效仍不容乐观。雌激素能够促进 NSCLC 细胞的增殖，且雌激素受体与NSCLC的表达和预后密切相关。雌激素受体调节剂及芳香化酶抑制剂能够逆转NSCLC患者对铂类化疗药物的耐药性，并能增强表皮生长因子受体酪氨酸酶抑制剂的疗效。“,”At present,the morbidity and mortality of lung cancer has been increasing year by year.With the progress of the comprehensive treatment methods such as surgery ,the short-term efficacy of non-small cell lung cancer (NSCLC) has been greatly improved,but the long-term efficacy is still not optimistic.Estrogen can promote the proliferation of NSCLC cells,and the expression of estrogen receptor and NSCLC is closely related to the prognosis.Estrogen receptor modulators and aromatase inhibitors can reverse the drug resistance of NSCLC patients to platinum based chemotherapy ,and can strengthen the effect of epidermal growth factor receptor tyrosine kinase inhibitors .